At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors’ choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy. Listen to the podcast to hear Dr. Bardia explain: what an antibody-drug conjugate is the design of the TROPION-Breast01 study and the first results dato-DXd side effects how dato-DXd might fit into the current treatment landscape for metastatic breast cancer
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana